Terfenadine (single or associated) treatment of adverse reactions to foods.
Six groups of patients (total 105), affected by cutaneous signs and symptoms related to food ingestion were studied with regards to the clinical efficacy of some pharmacologic treatments: blind placebo, terfenadine alone, terfenadine associated with pirenzepine or rosaprostol or ranitidine or famotidine. Pharmacologic treatment by terfenadine alone showed poor clinical results, similar to placebo, while the associations of terfenadine with both cytoprotective drugs and anti-H2 receptor antagonists revealed significant clinical improvement which is more evident in those patients treated with cytoprotective drugs combination than those who were treated with anti-H2 antagonists.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000799:Angioedema / Q000188:drug therapy / Q000209:etiology; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D015738:Famotidine; D005260:Female; D005512:Food Hypersensitivity / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine / Q000008:administration & dosage; D011466:Prostanoic Acids / Q000008:administration & dosage; D011899:Ranitidine / Q000008:administration & dosage; D016593:Terfenadine; D013844:Thiazoles / Q000008:administration & dosage; D014581:Urticaria / Q000188:drug therapy / Q000209:etiology
D001559:Benzhydryl Compounds; D011466:Prostanoic Acids; D013844:Thiazoles; D010890:Pirenzepine; D015738:Famotidine; D016593:Terfenadine; D011899:Ranitidine; C035288:rosaprostol